Skip to main content

Table 3 Summary table of network meta-analysis results with the difference of restricted mean survival time and the hazard ratio for the six treatments compared with radiotherapy alone and the three efficacy endpoints

From: Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas

Treatment data

Overall survival

Progression-free survival

Locoregional control

20 trials, 5144 patients

26 comparisons, 2070 events

26 comparisons, 2489 events

26 comparisons, 915 events

rmstD(t*=10 years) (m)

Hazard ratio

rmstD(t*=10 years) (m)

Hazard ratio

rmstD(t*=10 years) (m)

Hazard ratio

P value heterogeneity/inconsistency

0.28

0.39

0.47

0.57

0.50

0.66

P value heterogeneity

0.29

0.30

0.22

0.24

0.26

0.35

P value inconsistency

0.33

0.54

0.87

0.96

0.84

0.92

RT*

 P score

0.14

0.15

0.03

0.04

0.03

0.03

CRT-AC

11.89 [7.40; 16.83]

0.65 [0.65; 0.76]

16.10 [11.70; 20.50]

0.62 [0.54; 0.71]

8.76 [5.21; 12.31]

0.53 [0.41; 0.68]

 P score

0.92

0.96

0.88

0.94

0.71

0.82

IC-CRT

8.71 [0.26; 17.16]

0.80 [0.62; 1.04]

16.12 [7.97; 24.27]

0.68 [0.54; 0.85]

5.97 [− 1.75; 13.68]

0.72 [0.51; 1.01]

 P score

0.72

0.63

0.86

0.79

0.47

0.50

CRT

7.67 [2.91; 12.43]

0.77 [0.63; 0.93]

10.59 [5.91; 15.26]

0.77 [0.65; 0.91]

5.08 [1.49; 8.68]

0.78 [0.58; 1.05]

 P score

0.64

0.71

0.50

0.52

0.36

0.38

IC-RT-AC

5.64 [− 4.50; 15.79]

0.87 [0.58; 1.31]

8.10 [− 1.88; 18.09]

0.83 [0.58; 1.17]

12.04 [3.40; 20.67]

0.47 [0.27; 0.82]

 P score

0.51

0.45

0.39

0.39

0.86

0.87

IC-RT

4.31 [− 2.79; 11.40]

0.92 [0.74; 1.13]

11.10 [4.37; 17.80]

0.79 [0.66; 0.93]

5.65 [− 1.36; 12.66]

0.83 [0.64; 1.07]

 P score

0.40

0.33

0.53

0.46

0.43

0.28

RT-AC

− 0.70 [− 11.01; 9.61]

0.96 [0.70; 1.30]

6.37 [− 4.79; 17.53]

0.84 [0.63; 1.11]

8.76 [− 0.74; 18.27]

0.63 [0.37; 1.06]

 P score

0.17

0.28

0.31

0.36

0.65

0.63

  1. m months, rmstD restricted mean survival time difference, RT radiotherapy, IC induction chemotherapy, CRT concomitant chemoradiotherapy, AC adjuvant chemotherapy
  2. *Reference treatment